Osteoprotegerin (OPG) in Induced Chronic Obstructive Pulmonary Disease (COPD) Sputum

Study Overview
=================
Brief Summary
-----------------
Evaluation of OPG level as disease markers has also been reported. It has been showed that patients with coronary artery disease had higher serum OPG levels than healthy volunteers. Moreover, serum OPG levels correlate with the number of stenotic coronary arteries

Detailed Description
-----------------
Osteoprotegerin (OPG) is a secreted glycoprotein containing 401 amino acids. It is a member of the tumour necrosis factor (TNF) receptor superfamily. It was firstly discovered as a protein regulating bone metabolism, inhibiting osteoclastogenesis, consequently, inhibiting bone resorption OPG is detected in lung using Northern blot analysis. It is likely that OPG would contribute to the pathogenesis of COPD and could be an effective disease marker of the disease

Official Title
-----------------
Osteoprotegerin (OPG) in Induced Sputum as a Novel Biomarker for COPD

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Procedure: Induced sputum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy non-smokers Age <35 years (younger group) Aged matched to COPD patients (older group) Normal spirometry Subjects are able to give informed consent Healthy smokers Age <35 years (younger group) Aged matched to COPD patients (older group) Normal spirometry Subjects are able to give informed consent Stable COPD patients: Stage I-IV according to the GOLD guidelines (3), (9) Current and/or ex-smokers with no less than 10 pack-year smoking history The subjects are able to give informed consent COPD patients with acute exacerbation: Stage I-IV according to the GOLD guidelines (3), (9) Exacerbation of COPD defined as an event in the natural course of the disease characterised by a change in the patient's baseline dyspnoea, cough and/or sputum beyond day to day variability sufficient to warrant a change in management (9) Current and/or ex-smokers with no less than 10 pack-year smoking history The subjects are able to give informed consent Asthma patients Patients diagnosed with asthma The subjects are able to give informed consent Bronchiectasis patients Patients with CT-confirmed bronchiectasis The subjects are able to give informed consent Cystic fibrosis patients Patients diagnosed with cystic fibrosis The subjects are able to give informed consent Exclusion Criteria: Healthy non-smokers and smokers Upper respiratory infection within the last 4 weeks. Subjects who have received research medication within the previous one month. Subjects unable to give informed consent. Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Stable COPD patients Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the visit Upper respiratory infection within the last 4 weeks Subjects who have received research medication within the previous one month Subjects unable to give informed consent Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study COPD patients with acute exacerbation Subjects who have received research medication within the previous one month Subjects unable to give informed consent Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Asthma Upper respiratory infection within the last 4 weeks Subjects who have received research medication within the previous one month Subjects unable to give informed consent. Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study. Bronchiectasis and cystic fibrosis Subjects who have received research medication within the previous one month. Subjects unable to give informed consent. Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers non smoker<br>18 volunteers | Procedure: Induced sputum<br>* Used Ultrasonic nebuliser<br>|
| Healthy volunteers smoker<br>15 volunteers | Procedure: Induced sputum<br>* Used Ultrasonic nebuliser<br>|
| Chronic Obstructive Pulmonary Disease COPD<br>39 volunteers | Procedure: Induced sputum<br>* Used Ultrasonic nebuliser<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sputum OPG | Sputum OPG as assessed by ELISA at baseline | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, asthma, smokers, healthy volunteers, bronchiectasis, cystic fibrosis